Vaccine News and Research

Latest Vaccine News and Research

Merck launches Oncology Collaborative Trials Network

Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers.

4 Jun 2010

WHO says H1N1 remains pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact "its most intense activity has passed in many parts of the world," Reuters reports (Lynn, 6/3).

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

Life Technologies makes equity investment in SGI

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has made an equity investment in Synthetic Genomics, Inc., a privately held company founded to commercialize synthetic genomic advances. Terms of the investment were not disclosed.

3 Jun 2010

Novel anti-malarial drug developed from blood thinner by Australian scientists

Malaria caused by a parasite that is borne in female mosquitoes and that spreads in humans through mosquito bites is a major public health problem and it kills more than a million people world wide each year. With the rise of resistance of many of the strains of the malaria parasite to most of the anti-malarial drugs the problem is escalating at an alarming pace.

2 Jun 2010

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

2 Jun 2010

Bangalore INDIA BIO 2010 inaugurated

Bangalore INDIA BIO 2010, India's premier Biotechnology event organized by the Department of Information Technology, Biotechnology and Science & Technology, Government of Karnataka, Vision Group on Biotechnology and MM Activ Sci-Tech Communications Co was inaugurated today by Shri B.S. Yeddyurappa, Hon'ble Chief Minister of Karnataka, and Shri Katta Subramanya Naidu - Hon'ble Minister for IT & BT, Information, Excise and BWSSB, Government of Karnataka.

2 Jun 2010

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

The University of Minnesota and Mayo Clinic, under the mantle of the Minnesota Partnership for Biotechnology and Medical Genomics, have formed a strategic research relationship with the Karolinska Institute of Stockholm, Sweden, the top-rated medical research university in Europe. Leaders of each institution signed memoranda of understanding to commit to the formal ongoing collaboration, called the Frontiers of Biomedical Research.

2 Jun 2010

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

Platelets play important role in cerebral malaria: Research

Scientists are making strides against cerebral malaria, a fatal form of malaria in children that can ravage the brain and is extremely difficult to treat. New research points to platelets - known for their role in blood clotting - as playing an important role in the disease, stimulating the immune system and turning on molecules that increase inflammation. The inflammation leads to the obstruction of blood vessels in the brain, causing brain damage similar to that seen with a stroke.

2 Jun 2010

Plans to continue flu vaccination ban – intensive investigations ongoing

In the first quarter of this year nearly 300 children across Australia fell ill with fevers, vomiting and convulsions following administration of the seasonal flu vaccine.

2 Jun 2010

TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine technology

TapImmune Inc. announced that it has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune.

2 Jun 2010

Prototype breast cancer vaccine shows promising results in mice

US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.

2 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

Merck launches Oncology Collaborative Trials Network

WHO says H1N1 remains pandemic

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Amorfix Life Sciences signs licensing agreement with PREVENT

Life Technologies makes equity investment in SGI

Novel anti-malarial drug developed from blood thinner by Australian scientists

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

Bangalore INDIA BIO 2010 inaugurated

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Research findings advance the effort to develop AIDS vaccine

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

Platelets play important role in cerebral malaria: Research

Plans to continue flu vaccination ban – intensive investigations ongoing

TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine technology

Prototype breast cancer vaccine shows promising results in mice

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in